API Raw Material Ticagrelor Powder Ticagrelor

Ticagrelor is an oral antiplatelet agent that belongs to a class of drugs known as P2Y12 receptor inhibitors. It works by reversibly binding to the P2Y12 receptor on platelets, preventing the activation of the GPIIb/IIIa receptor and subsequent platelet aggregation. This action reduces the risk of thrombotic events in patients with acute coronary syndromes. It is known for its rapid onset and consistent platelet inhibition without requiring metabolic activation.

Ticagrelor is a novel antiplatelet drug commonly used in the treatment of arterial thrombotic diseases, with core functions focusing on inhibiting platelet aggregation and preventing thrombosis. It is widely applied in the treatment and secondary prevention of acute coronary syndrome (including unstable angina pectoris, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction). It can quickly inhibit platelet aggregation, reduce the risk of thrombotic events (such as recurrent myocardial infarction, stroke, and cardiovascular death) in patients with acute coronary syndrome, and is especially suitable for antithrombotic treatment after percutaneous coronary intervention (PCI). Combined with aspirin, it can form a dual antiplatelet regimen, significantly improving the long-term prognosis of patients.